Camrelizumab Combined With Apatinib and Gemcitabine Plus Cisplatin as First-line Therapy for Patients With Inoperable/Metastatic Biliary Tract Cancer (BTC): An Open-label, Single-arm, Single-center, Phase Ib/II Clinical Study
Latest Information Update: 10 Jan 2025
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer; Gallbladder cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 27 Feb 2023 New trial record